Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- United States
- Temporary Measures to Defer Medicare Reimbursement Cuts and Prolong
Basic Health Insurance for Children
- Decline in Drug Imports
- Pressure for the Introduction of a Medicare Formulary
- PBMs Commit to Greater Transparency
- Call for Infl ation-Based Medicaid Rebates
- Copayment Reductions and Waivers for Generics and Chronic Disease
Therapies
- Momentum for Universal Health Insurance
- Benefi t Cuts at Age 65 Judged Acceptable
- European Union
- Responses to Public Consultation on the Future of Pharmaceuticals in
Europe
- France
- French Health Care System at a Crossroads
- Social Security Budget Increases Pressure on Pharmaceutical Industry
- Potential Reform of Coverage of Treatments for Chronic Diseases
- Germany
- Market Trends in 2007
- Pharmaceutical Budget for 2008
- Introduction of New Reference Pricing Groups
- Continuing Debate Over Procedures for Health Economic Evaluation
- Continued Growth in Rebate Contracts
- Italy
- Spain
- Amendments to the Reference Pricing System
- United Kingdom
- Proposed Amendments to NICE' s Methods for Technology Appraisals
- OFT Report on Direct-to-Pharmacy Distribution
- Abolition of Prescription Charges in Scotland
- Japan
- Overhaul of Pricing and Reimbursement System Unlikely in 2008
- Change to Prescription Form to Stimulate Generics Substitution
- Outlook and Implications for the Pharmaceutical Industry
Tables:
- 1. New Reference Pricing Groups Implemented in Germany Effective January
1, 2008
- 2. 2007 Retail Prices and New Reference Prices of Largest Pack Size of
Nebilet
- 3. Proposed Changes to the Hierarchy of National Health Insurance Price
Premiums in Japan
- 4. Revision Rates for Japanese Reimbursement Prices, 1994-2006
Figures:
- 1. Uninsured U.S. Residents, 2002-2006
- 2. Ten Most Common Registered Chronic Diseases in France, 2006
- 3. Annual Sales of Drugs Facing Patent Expiration in Italy in 2008
|
Related Report
|
View Cart
